Prevalence of UGT1A1*28 promoter polymorphism in the omani population: Implications for irinotecan treatment in GI cancer

被引：0
|
作者：
Al Ghoche, A. A. G. [1 ]
Al Zadjali, S. [2 ]
Pullanhi, A. [3 ]
Alfahdi, A. [3 ]
Al-Balushi, A. [2 ]
Al-Mahrouqi, N. [2 ]
Abu Omar, R. [3 ]
Salman, B. [4 ]
Almoundhri, M. [1 ]
机构：
[1] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Oncol Dept, Muscat, Oman
[2] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Res Labs, Muscat, Oman
[3] Sultan Qaboos Univ Hosp, Muscat, Oman
[4] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Pharm Dept, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
525P
引用
收藏
页码：S208 / S209
页数：2
相关论文
共 50 条
  • [31] Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients
    Geng, Shuai
    Shen, Yulong
    Zhang, Chen
    Wang, Nan
    Gao, Xinyue
    Luo, Xinyu
    Shi, Ning
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [32] Uridine diphosphate glucuronosyltransferase 1A1*28 (UGT1A1*28) and irinotecan pharmacokinetics
    Toffoli, Giuseppe
    Corona, Giuseppe
    Cattarossi, Giulio
    Cecchin, Erika
    Buonadonna, Angela
    Colussi, Anna Maria
    D'Andrea, Mario
    Vinante, Orazio
    Sandri, Paolo
    Frustacci, Sergio
    ANNALS OF ONCOLOGY, 2004, 15 : 17 - 17
  • [33] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    Journal of Traditional Chinese Medicine, 2017, 37 (01) : 35 - 42
  • [34] Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project
    Hikino, Keiko
    Ozeki, Takeshi
    Koido, Masaru
    Terao, Chikashi
    Kamatani, Yoichiro
    Murakami, Yoshinori
    Kubo, Michiaki
    Mushiroda, Taisei
    JOURNAL OF HUMAN GENETICS, 2019, 64 (12) : 1195 - 1202
  • [35] The UGT1A1*28 promoter polymorphism in Gilbert's disease is associated with a second novel UGT promoter polymorphism impacting hepatic and extrahepatic drug metabolism
    Lankisch, TO
    Barut, A
    Krone, B
    Fiebeler, A
    Manns, MP
    Strassburg, CP
    HEPATOLOGY, 2004, 40 (04) : 276A - 276A
  • [36] UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
    Yang, Yuwei
    Zhou, MengMeng
    Hu, Mingjun
    Cui, Yanjie
    Zhong, Qi
    Liang, Ling
    Huang, Fen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e479 - e489
  • [37] Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism
    Gil, Justyna
    Sasiadek, Maria M.
    BIOMARKERS IN MEDICINE, 2012, 6 (02) : 223 - 230
  • [38] Is there a clinical benefit in testing for UGT1A1*28 prior to irinotecan therapy?
    Kularatne, Bihani Yoshana
    Marinaki, Anthony
    Karavasilis, Vasilis
    Spicer, James F.
    Ross, Paul J.
    Pectasides, Dimitrios G.
    Makatsoris, Thomas
    Pentheroudakis, George E.
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [39] The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
    Chen, Yi-Jing
    Hu, Fei
    Li, Chun-Yan
    Fang, Jue-Min
    Chu, Li
    Zhang, Xi
    Xu, Qing
    BIOMARKERS, 2014, 19 (01) : 56 - 62
  • [40] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2017, 37 (01) : 35 - 42
12345